Goldfinch Bio
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Goldfinch Bio sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Goldfinch Bio: 5 sponsored US clinical trials, none currently recruiting.
Goldfinch Bio sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetic Nephropathies, with 1 trials.
Upper-quartile sponsor footprint
Goldfinch Bio sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
NCT04950114
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
NCT04880291
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
NCT04387448
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
NCT04235621
FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects
NCT03970122
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Therapeutic Areas
How the Goldfinch Bio early-phase archive is shaped
5 indexed studies, none listed as recruiting (0% open); 2 completed (40%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Diabetic Nephropathies (1 trial), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Goldfinch Bio: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Goldfinch Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Goldfinch Bio page
5 registered trials is a research-attention snapshot, not an endorsement of Goldfinch Bio or any single study.
- None of Goldfinch Bio's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Diabetic Nephropathies is the condition Goldfinch Bio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Nephropathies trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Goldfinch Bio pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.